Are AHA/ACC and ESC/ESA Guidelines for Cardiovascular Assessment in Non-Cardiac Surgery Suitable for Fragility Fracture Patients? by Rostagno, C
Short Communication Open Access
Journal of Perioperative MedicineJourn
al 
of 
Peri
operative Medicine
Rostagno, J Perioper Med 2017, 1:1
Volume 1 • Issue 1• 1000101J Perioper Med, an open access journal 
Kyewords: Non-cardiac surgery; Fragility fracture; Comorbidity; 
AHA/ACC guideline; ESC/ESA guideline
Short Communication
In developed countries fragility fractures, and in particular 
fractures of third proximal of femur, is one of the more frequent causes 
of admission to emergency department [1]. Only in Italy 90,000 patients 
are admitted every year for surgical treatment of hip fracture [1,2]. 
Mean age of these patients is 85 years and a history of cardiovascular 
disease is found in more than 30% [3]. Moreover at least 50% of these 
patients have severe functional impairment, with inability to cover 
more than 50 meters without help, before trauma. Surgery performed 
within 48 hours from trauma has been demonstrated to significantly 
improve 30 day and 1 year survival [4-6]. However, these results may 
be biased by the delay needed for stabilization in patients with more 
severe clinical conditions at admission. Heart failure and perioperative 
myocardial infarction are the more threatened cardiac complications 
and the more frequent causes of death in first 30 days after hip fracture 
surgery [7]. Severe transient hypotension may occur as a consequence 
of surgical bleeding and decrease of systemic vascular resistance due to 
spinal anesthesia. A significant decrease of cardiac output may lead to 
ominous consequences in patients with severe aortic stenosis and/or 
severe coronary artery disease. 
Rapid and careful preoperative assessment allows identifying 
high risk patients and decreasing preventable in-hospital deaths in 
candidates to narrow time-dependent surgery. The choice of proper 
anesthesiology strategy and perioperative treatment, including 
postoperative observation in ICU when needed, may improve in 
hospital survival. The introduction of geriatricians in orthopedic 
wards and thereafter of orthogeriatrics teams with a multidisciplinary 
approach has significantly improved in hospital and long term 
outcomes in patients with hip fracture [8-10]. In Florence exists since 
2011 a multidisciplinary team including internal medicine specialists, 
geriatrics, orthopedics, anesthesiologists that may contribute, through 
careful clinical evaluation to safely decrease time to surgery, decrease 
post-operative complications and the length of hospitalization [11]. Are 
in this setting ACC/AHA and ESC/ESA guidelines effectively suitable 
for adequate cardiovascular assessment? [12,13]. The first aspect to 
be discussed is whether hip fracture surgery should be considered a 
surgical procedure at intermediate risk as reported in the guidelines? 
The hospital mortality in patients undergoing hip surgery fracture 
ranges between 2.5 and 9% while 1 years survival is comprised between 
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Abstract
In Italy more than 90,000 patients are admitted every year for surgical treatment of hip fracture. In these 
elderly patients frailty and the presence of 2 or more comorbidities are associated with a prognosis both a 30 
days and at 1 year. Heart failure and myocardial infarction are the more threatened cardiac complications and the 
more frequent causes of death in first 30 days after surgery for hip fracture. High risk patients may be identified by 
careful and rapid preoperative evaluation in order to decrease preventable in-hospital death in subjects patients 
candidate to narrow time-dependent surgery. In our review we tried to evaluate whether the ACC/AHA and ESC/
ESA guideline are effectively suitable for adequate cardiovascular assessment in this particular high risk population.
65 to 75% [14-17]. In our opinion therefore the frail population 
undergoing hip fracture surgery should be considered as a high risk 
group undergoing high risk surgery. 
Determination of functional capacity is considered a main step in 
preoperative cardiac risk assessment for non-cardiac surgery in AHA/
ACC or ESC/ESA guidelines: Patients with high functional capacity 
have been demonstrated to have a good prognosis after non-cardiac 
surgery also in presence of stable coronary artery disease. Limited 
activity before trauma may mask symptoms, in particular chest pain 
and dyspnea, even in presence of history of heart disease. Since most 
has a poor functional capacity before trauma (largely 4 METs) we 
cannot rely on this feature for assessment of cardiovascular risk in 
patients with hip fracture.
In patients undergoing hip fracture surgery the overall rate of 
postoperative heart failure is close to 7% within seven postoperative 
days and 22% within one postoperative year. Postoperative heart failure 
was significantly more common among those with preoperative heart 
failure and coronary heart disease. In these patients one year mortality 
was 37% [18]. In a prospective observational study factors related to 
post-operative heart failure were age ≥ 90 years (OR 4.1), male gender 
(OR 1.8), and a history of cardiovascular disease (OR 2.3) [19].
The risk of heart failure or death in post-operative period is 
significantly increased in patients with previously undiagnosed severe 
valve heart disease, mainly aortic stenosis and mitral regurgitation. 
According to ESC guidelines routine rest echocardiography may be 
considered (evidence class II, level B) for the evaluation high-risk 
surgery patients while recommendation class I evidence level A has 
been provided for patients with heart failure and recommendation class 
I evidence level C for patients with physical signs of severe valve disease. 
According to SIGN guidelines echocardiography is recommended in 
order to better stratify surgical risk and define anesthesiologist strategy 
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in suspected aortic stenosis, provided that examination do not delay 
surgery [20].
Several information may be provided by echocardiography useful 
both to obtain more accurate risk stratification and to stabilize clinical 
conditions. First evaluation of inferior vena cava diameter may allow 
assessing volume status and correcting before surgery conditions of 
hypovolemia, which affects adversely clinical outcome. The functional 
evaluation of left and right ventricle is useful to avoid unnecessary 
fluid administration which may precipitate heart failure in particular 
in post-operative period. In patients with suspect heart valve disease, 
assessment of hemodynamic severity of defects may favor a more 
accurate peri-operative management. Finally other parameters, in 
particular pulmonary artery pressure, may provide prognostic elements. 
According to data from our center in patients with mild-moderate heart 
failure a RV/RA gradient>40 mmHg is independently associated with 
a lower in hospital and 3 months survival. We believe that in patients 
with hip fracture echocardiography performed at admission may give 
several anatomic and functional parameters, for example inferior vena 
cava diameter to assess volume status, that may improve peri-operative 
management and decrease in hospital complications. Further studies 
must be addressed to evaluate cost-effectiveness in hip fracture units in 
which bed-side echocardiography may available routinely. 
A evidence class II, level B is attributed to NT-pro-BNP and BNP 
measurements for obtaining independent prognostic information for 
perioperative and late cardiac events in high-risk patients. A few reports 
suggest the usefulness of NT-pro-BNP levels as prognostic factor hip 
fracture surgery [21,22]. In 75 patients with mild moderate heart failure 
referred to our Hospital for hip fracture NT-pro-BNP values 2000 pg/
ml, were associated with a two folds increase in 3 months mortality 
(64% sensitivity and 70% specificity) [23].
Perioperative myocardial infarction rarely complicates clinical 
course in patients with hip fracture, however clinical symptoms 
are uncommon. Patients with perioperative myocardial infarction 
have a higher 30 days and 1-year mortality. ESC guidelines suggest 
assessment of cardiac troponins in high-risk patients, both before and 
48-72 hours after major surgery, may be considered (evidence class II 
level b). According to the diagnostic criteria used in different studies 
the incidence of perioperative acute myocardial infarction in patients 
hospitalized for hip fracture varies from 6%-35% [24-26].
A retrospective study from Olmsted County, Minnesota reported 
among 1212 consecutive patients admitted for hip fracture a 13.8% 
incidence of perioperative myocardial infarction, most occurring in the 
first 48 hours after surgery [27]. In-hospital mortality was 14.4% while 
1-year survival was 60.5%. The authors conclude that the majority of 
patients did not experience ischemic symptoms and required cardiac 
biomarkers for the diagnosis.
Hietala observed an increase of TnT in 35.5% in hip fracture 
surgery [28]. Near half of these patients showed troponin increase 
before surgery. Overall 30-day mortality was 17% and 24% in 
subgroup with values 0.15 µg/L. In this study increase of troponin was 
the only independent predictor of 30-day mortality. Fisher showed 
that a perioperative increase of troponin I 0.06 µg/L was associated 
with longer hospitalization and referral to long term residential care 
facilities. A troponin I 1 µg/L was predictor of all-cause mortality with 
98% specificity and 89% negative predictive value.
Perioperative myocardial infarction has been often the first clinical 
manifestation of coronary heart disease. 56% of patients referred for 
surgical treatment of hip fracture that showed an increase of troponin 
levels had no previous history of coronary artery disease.
The finding that a significant troponin increase is found before 
surgery in 20-40% of perioperative myocardial infarctions suggests 
that troponin assay should be performed at hospital admission [28]. 
In patients with elevated TnI at admission clinical stabilization may be 
needed before surgery. In our experience time to surgery was longer in 
patients with elevated preoperative TnI (4.4 days) compared with those 
with normal TnI value at admission (2.5 days).
Nevertheless hospital and long-term mortality were lower, although 
not statistically significant, in patients with preoperative elevated TnI 
than in patients with postoperative myocardial infarction [29].
At present no indication is provided by ESC/ESA or AHA/ACC 
guidelines for early invasive evaluation in subjects suffering from 
perioperative myocardial infarction after non-cardiac surgery and 
to our knowledge the effects of early revascularization have not been 
previously studied in these patients In our institution 13/99 patients 
with peri-operative myocardial infarction underwent coronary 
angiography and subsequent revascularization after hip surgery, 12 
percutaneous and 1 surgical (associated with mitral valve repair for 
severe mitral valve regurgitation). Eleven (82%) were alive at 1 year of 
follow-up in comparison to 38/88 (42%) patients treated with medical 
therapy.
An emergent issue in preoperative evaluationof hip fracture 
patients is the growing number (about 20%) with on going anticoagulant 
(warfarin or direct oral anticoagulants) or double antiplatelet treatment.
Bleeding risk is increased in these during non-cardiac surgery; 
however this risk will be outweighed by the benefit of anticoagulant-
antiplatelet therapy. Since hip fracture treatment is a close time dependent 
surgery restoration of coagulative activity is usually a primary need for 
anesthesiologists and surgeons. The topic is not clearly addressed by 
guidelines. Anticoagulant doses of LMWH (bridge therapy) have been 
suggested in high risk patients (mechanical valve in mitral position, 
previous stroke or TIA, recent venous thromboembolism) [30], however 
an increase of bleeding complications of has been provided for “full 
doses” of LMWH [31]. LMWH at dosage used for DVT prophylaxis 
is safe in most patients without a higher thromboembolic risk and a 
decrease of hemorrhagic complications. Reversal of warfarin effects 
with vitamin K administration may significantly shorten the time to 
surgery in anti-coagulated patients. Limited evidence exists on effects 
of low-dose vitamin K administration before hip surgery, suggesting a 
decrease in time to surgery without an increased embolic risk. 
Surgery should be delayed 48-72 hours in in patients treated with 
direct anticoagulant agents at the moment of trauma. Few data were 
published about the impact of oral anticoagulation on time to surgery 
in patients hospitalized with hip fracture. Tran et al. reported that 
patients in DOAC had a longer time to surgery (66.9 h; IQR: 38.1 to 
78.9) compared to a to the control group (26.2 h; IQR: 17.3 to 40.6; p b 
0.0001) [32].
Similarly in our experience in 31 patients in DOA treatment time 
to surgery was 4.0 ± 2.58 days vs. 2.65 ± 1.64 days in control group. We 
did not find significant differences in hospital mortality between two 
groups (3.9% in DOA patients in comparison to 3% in controls).
Prothrombin complex concentrates activated prothrombin complex 
concentrates (FEIBA) may contribute to “reverse” anticoagulation 
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28. Hietala P, Strandberg M, Strandberg N, Gullichsen E, Airaksinen KE, et 
al. (2013) Perioperative myocardial infarctions are common and often 
induced by Xa factor inhibitors in order to decrease the time to surgery 
however no data exist in patients with hip fracture [33,34].
Recently REVERSE- AD study, evaluated the effects of 
Idarucizumab i.v (5 mg) in reversing dabigatran effects. Were enrolled 
two groups: Group A (patients who had uncontrolled bleeding) and 
Group B (patients who needed an urgent surgical or interventional 
procedure) [35]. In this second group 20% of patients had hip fracture. 
The study showed that the surgical/interventional procedure was 
started on average 1.6 hours after Idarucizumab administration with 
normalization of hemostasis in 93.4% before starting the procedure. 
The authors did not show provide data isolated data for hip 
fracture surgery. Further studies are needed to further assess the cost-
effectiveness of this approach.
The risks associated with the operative management of patients on 
double antiplatelet agents include increased intra-operative bleeding 
and a higher risk of spinal haematoma where regional anaesthesia 
is used. In patients needing surgery within a few days, current ESC 
Guidelines recommend withholding clopidogrel and ticagrelor for five 
days and prasugrel for seven days prior to surgery unless there is a high 
thrombotic risk. 
Withdrawal of antiplatelet agents and waiting reverse of 
pharmacological effects before surgery is associated with an unacceptable 
delay in surgery (8 vs. 2 days) and significant increase in the risk of 
perioperative stent thrombosis, overall hospital complications, and 
mortality [36]. Hip surgery has been performed safely under general 
anaesthesia in patients with ongoing double antiplatelet treatment for 
recent coronary stenting without a significant increase in morbidity 
and mortality. However they showed an increase in the need for blood 
transfusions [37-39]. 
Rarely platelet transfusion may be needed for uncontrollable 
bleeding. Simple validated score systems may be useful to stratify 
surgical risk in analogy with cardiac surgery. In the risk calculator 
score proposed by Pugely et al. risk variables were variables American 
Society of Anesthesia score, dependence in BADL, active malignancy, 
race, cardiopulmonary disease, renal failure, longer surgical time and 
open versus percutaneous surgery [40]. A new prognostic score index, 
is presently under validation at our institution.
In conclusion ACC/AHA and ESC guidelines have several 
limitations for the assessment of cardiovascular risk in patients who 
need time dependent surgery as needed for hip fracture. A careful 
clinical preoperative evaluation including echocardiography may favor 
to decrease the risk of severe complications and preventable deaths.
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